Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
An affiliate of NTRA has filed a notice to sell 285 shares of common stock, with a proposed aggregate sale price of $74,667.15, expected on July 27, 2026. The filing also references a prior grant of 9,405 Restricted Stock Units for services rendered on January 26, 2024 and lists multiple common stock sales by Jonathan Sheena over the past three months.
An affiliate of NTRA has filed a Form 144 indicating an intent to sell common stock acquired from Restricted Stock Units granted for services rendered. The notice covers up to 68,976 shares, and lists several recent sales of common stock over the prior three months.
An affiliate of NTRA reporting person Daniel Rabinowitz filed a notice of proposed sale of 873 shares of common stock, with an aggregate market value of $228,717.27, to be sold through a broker on NASDAQ on 07/27/2026. The filing notes these shares relate to Restricted Stock Units originally acquired on 01/26/2024 for services rendered, in a grant of 27,433 units. It also discloses prior sales of common stock over the past three months in several transactions by Rabinowitz.
Solomon Moshkevich filed a notice to sell up to 998 shares of common stock, with an aggregate market value of 261,466.02, on or after 07/27/2026 on NASDAQ. Common stock underlying Restricted Stock Units acquired on 01/26/2024 for 31,352 shares as payment for services rendered is listed as the source. The filing also reports several prior open-market sales over the past three months, including transactions of 3,000 shares on multiple dates and smaller trades, each with stated aggregate proceeds.
John Fesko filed to sell common stock of the issuer under Rule 144. The securities to be sold consist of common stock acquired on 01/26/2024 as Restricted Stock Units from the issuer in connection with services rendered, totaling 31,352 shares.
The filing also lists prior sales of the same common stock class during the past three months, including 1,688 shares on 04/27/2026 for $344,516.88, 291 shares on 05/01/2026 for $59,992.56, and 1,438 shares on 05/26/2026 for $291,683.56.
E*TRADE Corporation has a notice of proposed sale of common stock filed by insider Steven Chapman. The form indicates an intention to sell up to 2,163 shares of common stock, with an aggregate market value of $566,684.37 as of 07/27/2026 on NASDAQ.
The shares relate to Restricted Stock Units granted on 01/26/2024 for services rendered, with a total of 86,220 units. The filing also lists Chapman’s sales of common stock during the prior three months, including 41,124 shares on 06/04/2026 for $9,089,777.54, 902 shares on 05/01/2026 for $185,956.32, and 5,838 shares on 04/27/2026 for $1,191,774.74.
An affiliate of the company with ticker NTRA, identified as Michael Brophy, filed a notice of intent to sell 772 shares of common stock, with an indicated value of $202,256.28, through a broker on 07/27/2026 on NASDAQ. The filing also notes a prior acquisition of 31,352 restricted stock units on 01/26/2024 from the issuer for services rendered, and reports recent sales over the past three months totaling several thousand shares across four transactions.
Natera, Inc. insider Sheena Jonathan, a director and co‑founder, reported pre‑planned sales of common stock held by family trusts. Caraluna 1 and Caraluna 2 Trusts sold a total of 1,500 shares on July 15, 2026 at weighted‑average prices between $272.56 and $276.38 per share under a Rule 10b5-1 trading plan adopted June 7, 2024. The shares are held for trust beneficiaries, and Jonathan disclaims beneficial ownership. A separate holdings entry reports 246,202 common shares held directly.
Natera, Inc. director Rowan E Chapman sold 135 shares of Common Stock on July 15, 2026 at an average price of $274.82 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on December 12, 2025, leaving Chapman with 4,663 shares held directly.
Natera, Inc. director and co‑founder Sheena Jonathan reported open‑market sales of 3,150 shares of common stock on July 13, 2026, at weighted‑average prices from $262.7160 to $268.3870 per share under a Rule 10b5‑1 trading plan adopted December 12, 2025. After these transactions, she reports 246,202 shares held directly, and 18,782 shares in each of the Caraluna 1 Trust and Caraluna 2 Trust held for trust beneficiaries, for which she disclaims beneficial ownership.